Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure

Eur J Heart Fail. 2020 May;22(5):901-903. doi: 10.1002/ejhf.1812. Epub 2020 Apr 3.

Authors

Susan Stienen¹, João Pedro Ferreira¹, Bertram Pitt², John G Cleland³, Pierpaolo Pellicori³, Nicolas Girerd¹, Patrick Rossignol¹, Faiez Zannad¹

Affiliations

¹ Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
² Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
³ Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow and National Heart & Lung Institute, London, UK.

PMID: 32243646
DOI: 10.1002/ejhf.1812

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Collagen Type I
Eplerenone
Heart Failure* / drug therapy
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use
Myocardial Infarction* / complications
Myocardial Infarction* / drug therapy
Peptide Fragments
Procollagen
Spironolactone
Ventricular Dysfunction, Left* / diagnosis

Substances

Collagen Type I
Mineralocorticoid Receptor Antagonists
Peptide Fragments
Procollagen
Spironolactone
Eplerenone